Lilly’s GLP-1 Pill Outperforms Older Novo Drug

Drug Performance & Expectations - The drug's performance in obesity studies has underperformed investor expectations [2] - In diabetes studies, the drug has slightly exceeded investor expectations [2] - Weight loss achieved is approximately 11%, falling short of the hoped-for 15% efficacy aligned with weight loss shots [3] Market Impact & Prescription - Doctors are expected to prescribe the drug widely if approved, due to the convenience of a pill form [3] - The pill version is anticipated to be a significant advancement in the obesity market, offering patients a new treatment option [1][3]